Filgotinib-treated rheumatoid arthritis patients with high baseline neutrophil-to-lymphocyte ratio show better clinical response rates and patient-reported outcomes

Bibliographic Details
Main Authors:	Taylor, P, Downie, B, Kim, S, Hawtin, R, Moots, R, Takeuchi, T
Format:	Conference item
Language:	English
Published:	BMJ Publishing Group 2021

Patients with high baseline neutrophil-to-lymphocyte ratio exhibit better response to filgotinib as treatment for rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2024)

Selective inhibition of Janus kinase 1 (JAK1) by filgotinib modulates the disease-associated whole blood transcriptional profile of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
by: Alejandro Balsa, et al.
Published: (2023-09-01)

Filgotinib for the treatment of rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

Concomitant use of statins in filgotinib-treated patients with rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2021)

Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis
by: Jeffrey R. Curtis, et al.
Published: (2023-12-01)

The evaluation of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with rheumatoid arthritis with and without ocular complications
by: Shirin Assar, et al.
Published: (2021-12-01)

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-severely Active Rheumatoid Arthritis (FINCH3)
by: Taylor, P, et al.
Published: (2020)

Neutrophil Lymphocyte Ratio as an Inflammatory Marker in Rheumatoid Arthritis
by: Muhammad Qasim Khan Tareen, et al.
Published: (2023-10-01)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
by: Bernard Combe, et al.
Published: (2022-10-01)

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate (FINCH1)
by: Taylor, P, et al.
Published: (2020)

Diagnostic Value of Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and Monocyte-to-Lymphocyte Ratios for the Assessment of Rheumatoid Arthritis in Patients with Undifferentiated Inflammatory Arthritis
by: Byung-Wook Song, et al.
Published: (2022-07-01)

The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2018)

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2024)

Effect of filgotinib on pain in patients with rheumatoid arthritis: results from phase 3 clinical trials
by: Pope, J, et al.
Published: (2021)

Filgotinib modulates inflammation-associated peripheral blood protein biomarkers in adults with active rheumatoid arthritis and prior inadequate response to methotrexate
by: Tanaka, Y, et al.
Published: (2023)

Red cell distribution width and neutrophil-lymphocyte ratio as inflammatory markers in patients with rheumatoid arthritis
by: Shekhar Kushwaha, et al.
Published: (2023-03-01)

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-07-01)

Platelet/lymphocyte, neutrophil/lymphocyte, and lymphocyte/monocyte ratios as biomarkers for rheumatoid arthritis: correlation with disease activity
by: Sahar A. Elsayed, et al.
Published: (2023-08-01)

Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotinib in MTX-naive adults with moderately-to-severely active rheumatoid arthritis (RA) (FINCH3)
by: Taylor, PC, et al.
Published: (2020)

The combination of baseline neutrophil to lymphocyte ratio and dynamic changes during treatment can better predict the survival of osteosarcoma patients
by: Longqing Li, et al.
Published: (2023-11-01)

Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-11-01)

Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives
by: Tanaka Y, et al.
Published: (2023-10-01)

Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid
by: Taylor, P, et al.
Published: (2018)

Neutrophil‐to‐monocyte ratio is the better new inflammatory marker associated with rheumatoid arthritis activity
by: Jamil M. A. S. Obaid, et al.
Published: (2023-08-01)

Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b trials
by: Tarrant, J, et al.
Published: (2020)

Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
by: Yoshiya Tanaka, et al.
Published: (2023-09-01)

The Relationship between Hematological Markers of Systemic Inflammation (Neutrophil-To-Lymphocyte, Platelet-To-Lymphocyte, Lymphocyte-To-Monocyte Ratios) and Ultrasound Disease Activity Parameters in Patients with Rheumatoid Arthritis
by: Bożena Targońska-Stępniak, et al.
Published: (2020-08-01)

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
by: Yoshiya Tanaka, et al.
Published: (2022-11-01)

Prognostic values of baseline cortisol levels and neutrophil to lymphocyte ratio in COVID-19
by: Erturk Sengel Buket, et al.
Published: (2023-01-01)

Associations of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio and Monocyte-to-Lymphocyte Ratio with Osteoporosis and Incident Vertebral Fracture in Postmenopausal Women with Rheumatoid Arthritis: A Single-Center Retrospective Cohort Study
by: Byung-Wook Song, et al.
Published: (2022-06-01)

Assessment of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with high myopia
by: Xin Wang, et al.
Published: (2022-11-01)

Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Patients with Retinal Artery Occlusion
by: Mahmut Atum, et al.
Published: (2020-04-01)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
by: Raj Verma, et al.
Published: (2023-06-01)

Prognostic Value of Neutrophils-to-Lymphocytes Ratio and Platelets-to-Lymphocytes Ratio in Sepsis Patients With Lymphopenia
by: Xianming Qiu, et al.
Published: (2024-01-01)

Elevated Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio after First Cycle of Chemotherapy and Better Survival in Esophageal Cancer Patients Receiving Concurrent Chemoradiotherapy
by: Ruo-Han Tseng, et al.
Published: (2022-11-01)

Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients
by: Thilo Gambichler, et al.
Published: (2022-09-01)

Assessment of neutrophil-lymphocyte and platelet-lymphocyte ratio in patients with hashimoto's thyroiditis
by: Gašić Sanja, et al.
Published: (2022-01-01)

Prognostic Significant of Neutrophil: Lymphocyte Ratio, Platelet – Lymphocyte ratio, and Lymphocyte – Monocyte ratio in Kurdish Patients with breast cancer
by: S. Khazaei, et al.
Published: (2022-07-01)

Filgotinib-treated rheumatoid arthritis patients with high baseline neutrophil-to-lymphocyte ratio show better clinical response rates and patient-reported outcomes

Similar Items

Similar Items